The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy

Current Drug Targets

Volumn 14, Issue 4, 2013, Pages 420-440

  Fiandalo, Michael V ^a   Wu, Wenjie ^a   Mohler, James L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; Apoptosis; Backdoor pathway; Dihydrotestosterone; Intracrine metabolism; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CASPASE 9; COMPLEMENTARY DNA; DUTASTERIDE; FLUTAMIDE; HYBRID PROTEIN; MELANOMA ANTIGEN; ORTERONEL; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; APOPTOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; DNA BINDING; DNA FRAGMENTATION; DRUG MEGADOSE; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HORMONE RESPONSIVE ELEMENT; HUMAN; LIGAND BINDING; MASS SPECTROMETRY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TISSUE MICROARRAY;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; APOPTOSIS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84876724319     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314040004     Document Type: Review

References (205)

1. Titus MA, Gregory CW, Ford OH, 3rd, et al. Steroid 5alphareductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4365-71.
2. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011; 17: 5844-9.
3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and androgen injection on serum phsphatases in metastatic carcinoma of prostate. Cancer Res 1941; 1: 293-97.
4. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.
5. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc 2010; 85: 77-86.
6. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012; 4: 167-78.
7. Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-4.
8. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-57.
9. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981; 41: 5070-5.
10. Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5: 1-17.
11. Mohler JL, Gregory CW, Ford OH, 3rd et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-8.
12. Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4653-7.
13. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-8.
14. Penning TM, Steckelbroeck S, Bauman DR, et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248: 182-91.
15. Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004; 9: 295-301.
16. Isaacs JT, D'Antonio JM, Chen S, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012.
17. D'Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer 2009; 16: 325-32.
18. Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010; 70: 1600-7.
19. Gregory CW, Johnson RT, Jr., Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898.
20. Lih FB, Titus MA, Mohler JL, Tomer KB. Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem 2010; 82: 6000-7.
21. Kalhorn TF, Page ST, Howald WN, et al. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21: 3200-6.
22. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011; 10: 20.
23. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006; 66: 2815-25.
24. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54.
25. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033-41.
26. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-15.
27. Suzuki K, Nishiyama T, Hara N, et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 301-6.
28. Chang KH, Li R, Papari-Zareei M et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108: 13728-33.
29. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61.
30. Mitsiades N, Sung CC, Schultz N, et al. Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. Cancer Res 2012; 72: 6142-52.
31. Mohler JL, Titus MA, Bai S, et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71: 1486-96.
32. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32: 81-151.
33. Godoy A, Kawinski E, Li Y, et al. 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 2011; 71: 1033-1046.
34. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17 betahydroxysteroid dehydrogenase 3. Nat Genet 1994; 7: 34-39.
35. Pomerantz M, Kantoff P. Clinical Progression to Castration-Recurrent Prostate Cancer. In Tindall D, Mohler J (eds): Androgen Action in Prostate Cancer. Springer Science + Business Media, LLC 2009; 57-72.
36. Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10: 149-54.
37. Azzouni F, Mohler J. Role of 5alpha-reductase inhibitors in prostate cancer prevention and treatment. Urology 2012; 79: 1197-205.
38. Yamana K, Labrie F, Luu-The V. Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig 2010; 2: 293-9.
39. Shah SK, Trump DL, Sartor O, et al. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 2009; 181: 621-6.
40. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
41. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-8.
42. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95.
43. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
44. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM. Safety, pharmacokinetics, and effiacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II openlabel study. J Clin Oncol 2010; 28.
45. Silverman RB. The potential use of mechanism-based enzyme inactivators in medicine. J Enzyme Inhib 1988; 2: 73-90.
46. Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012; 97: 507-16.
47. Berchem GJ, Bosseler M, Sugars LY, et al. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995; 55: 735-8.
48. Devi GR. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect 2004; 17: 127-134.
49. Bismar TA, Yoshimoto M, Duan Q, et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castrationresistant prostate cancer. Histopathology 2012.
50. Yoshimoto M, Ludkovski O, DeGrace D, et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes, chromosomes & cancer 2012; 51: 149-60.
51. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
52. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283-94.
53. Wallach D, Kang TB, Kovalenko A. The extrinsic cell death pathway and the elan mortel. Cell Death Differ 2008; 15: 1533-41.
54. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011; 3: 279-96.
55. Galluzzi L, Zamzami N, de La Motte Rouge T, et al. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12: 803-13.
56. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
57. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
58. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999; 13: 3179-84.
59. Ohtsuka T, Buchsbaum D, Oliver P, et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034-44.
60. Siu WP, Pun PB, Latchoumycandane C, Boelsterli UA. Baxmediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: Multiple protective roles of cyclosporin A. Toxicology and applied pharmacology 2008; 227: 451-61.
61. Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988; 13: 103-17.
62. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122: 552-62.
63. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989; 15: 233-50.
64. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50: 3748-53.
65. Colombel MC, Buttyan R. Hormonal control of apoptosis: the rat prostate gland as a model system. Methods Cell Biol 1995; 46: 369-85.
66. Lekas E, Johansson M, Widmark A, et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309-14.
67. Shabsigh A, Chang DT, Heitjan DF, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201-6.
68. Shabisgh A, Tanji N, D'Agati V, et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999; 140: 1920-6.
69. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab 2011; 300: E263-275.
70. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
71. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.
72. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21: 315-24.
73. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-77.
74. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal. J Biol Chem 2012; In Press: 1-16.
75. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998; 95: 7379-84.
76. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-19.
77. van Weerden WM, van Kreuningen A, Elissen NM, et al. Effects of adrenal androgens on the transplantable human prostate tumor PC-82. Endocrinology 1992; 131: 2909-13.
78. Titus MM, JM. 5alpha-Reductase Isozymes in Castration Recurrent Prostate Cancer. In Androgen Action in Prostate Cancer. Springer Science 2009.
79. Mohler JT, MA. Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer. In Androgen Action in Prostate Cancer. Springer Science 2009; 175-85.
80. Bielohuby M, Herbach N, Wanke R, et al. Growth analysis of the mouse adrenal gland from weaning to adulthood: time-and genderdependent alterations of cell size and number in the cortical compartment. Am J Physiol Endocrinol Metab 2007; 293: E139-46.
81. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
82. Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 1996; 226: 57-63.
83. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9.
84. Koivisto PA, Helin HJ. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 1999; 189: 219-23.
85. Miyoshi Y, Uemura H, Fujinami K, et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000; 43: 225-32.
86. Palmberg C, Koivisto P, Kakkola L, et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992-5.
87. Ford OH, 3rd, Gregory CW, Kim D, et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170: 1817-21.
88. Gottlieb B, Beitel LK, Nadarajah A, et al. The androgen receptor gene mutations database: 2012 update. Hum Mutat 2012; 33: 887-94.
89. Cavailles V, Dauvois S, L'Horset F, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 1995; 14: 3741-51.
90. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733-6.
91. Heery DM, Hoare S, Hussain S, et al. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem 2001; 276: 6695-702.
92. Mahajan MA, Samuels HH. Nuclear hormone receptor coregulator: role in hormone action, metabolism, growth, and development. Endocr Rev 2005; 26: 583-97.
93. Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998; 273: 92-101.
94. He B, Kemppainen JA, Voegel JJ, et al. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 1999; 274: 37219-25.
95. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000; 275: 22986-994.
96. Hsu CL, Chen YL, Yeh S, et al. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 2003; 278: 23691-8.
97. He B, Gampe RT, Jr., Kole AJ, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004; 16: 425-38.
98. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90.
99. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9.
100. Yeh S, Miyamoto H, Chang C. Hydroxyflutamide may not always be a pure antiandrogen. Lancet 1997; 349: 852-3.
101. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002; 161: 1467-74.
102. Peng Y, Li CX, Chen F, et al. Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor coactivator ARA70. Am J Pathol 2008; 172: 225-35.
103. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005; 25: 1238-57.
104. Bai S, Wilson EM. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008; 28: 1947-63.
105. Bai S, Grossman G, Yuan L, et al. Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol Hum Reprod 2008; 14: 107-16.
106. Askew EB, Bai S, Hnat AT, et al. Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem 2009; 284: 34793-808.
107. Karpf AR, Bai S, James SR, et al. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7: 523-35.
108. Askew EB, Bai S, Blackwelder AJ, Wilson EM. Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem 2010; 285: 21824-36.
109. Weigel NL, Moore NL. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 2007; 21: 2311-9.
110. van Laar JH, Bolt-de Vries J, Zegers ND, et al. Androgen receptor heterogeneity and phosphorylation in human LNCaP cells. Biochem Biophys Res Commun 1990; 166: 193-200.
111. Yeh S, Chang HC, Miyamoto H, et al. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J Med 1999; 48: 87-92.
112. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgeninduced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-5.
113. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-85.
114. Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10: 309-19.
115. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990; 173: 534-40.
116. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-3015.
117. Chen G, Wang X, Zhang S, et al. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005; 63: 395-406.
118. Li YD, Lu Y, Chen GC, Lu J. An S296R mutation in the human androgen receptor causes activation of the receptor by nonandrogenic steroids and stronger inhibition by the nuclear receptor corepressor N-coR. Clin Exp Pharmacol Physiol 2008; 35: 1252-7.
119. Berrevoets CA, Doesburg P, Steketee K, et al. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol 1998; 12: 1172-83.
120. Steinkamp MP, O'Mahony OA, Brogley M et al. Treatmentdependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69: 4434-42.
121. Gronemeyer H, Laudet V. Transcription factors 3: nuclear receptors. Protein Profile 1995; 2: 1173-308.
122. Laudet V, Gronemeyer H. The Nuclear Receptor FactsBook. Academic Press 2002.
123. Escriva H, Bertrand S, Laudet V. The evolution of the nuclear receptor superfamily. Essays Biochem 2004; 40: 11-26.
124. Shi XB, Ma AH, Xia L, et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62: 1496-502.
125. Monge A, Jagla M, Lapouge G, et al. Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci 2006; 63: 487-497.
126. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003; 23: 8563-75.
127. Hay CW, McEwan IJ. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One 2012; 7: e32514.
128. Sack JS, Kish KF, Wang C, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 2001; 98: 4904-9.
129. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53.
130. Krishnan AV, Zhao XY, Swami S, et al. A glucocorticoidresponsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 2002; 143: 1889-900.
131. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-8.
132. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5.
133. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-8.
134. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgendepleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-91.
135. Ceraline J, Cruchant MD, Erdmann E, et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004; 108: 152-7.
136. Takahashi H, Furusato M, Allsbrook WC, Jr. et al. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995; 55: 1621-1624.
137. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012; 287: 19736-49.
138. Marcias G, Erdmann E, Lapouge G, et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2010; 31: 74-80.
139. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
140. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-65.
141. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011; 71: 1656-67.
142. Yang X, Guo Z, Sun F, et al. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem 2011; 286: 36152-60.
143. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
144. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011; 18: R183-96.
145. Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 2001; 27: 309-19.
146. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
147. Zhao H, Coram MA, Nolley R, et al. Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression. J Urol 2012; 188: 2158-64.
148. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-25.
149. Zhang X, Morrissey C, Sun S, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011; 6: e27970.
150. Guo Z, Qiu Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 2011; 7: 815-22.
151. Le Page C, Koumakpayi IH, Alam-Fahmy M, et al. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006; 94: 1906-12.
152. Nanni S, Priolo C, Grasselli A, et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006; 4: 79-92.
153. Hornberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011; 6: e19059.
154. Jagla M, Feve M, Kessler P, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148: 4334-43.
155. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005; 24: 7465-74.
156. Murillo H, Huang H, Schmidt LJ, et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805.
157. Hiles ID, Otsu M, Volinia S, et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 1992; 70: 419-29.
158. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annual review of biochemistry 1998; 67: 481-507.
159. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963.
160. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews. Drug discovery 2005; 4: 988-1004.
161. Skeen JE, Bhaskar PT, Chen CC, et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer cell 2006; 10: 269-280.
162. Zhou H, Li XM, Meinkoth J, Pittman RN. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 2000; 151: 483-94.
163. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002; 277: 14040-7.
164. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 2003; 10: 537-60.
165. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-12.
166. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-12.
167. Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 2009; 8: 4032-9.
168. Ha S, Ruoff R, Kahoud N, et al. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 2011; 18: 245-55.
169. Dan HC, Cooper MJ, Cogswell PC, et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22: 1490-500.
170. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-86.
171. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76.
172. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res 2007; 13: 3585-90.
173. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO journal 1998; 17: 2215-23.
174. Bratton SB, Lewis J, Butterworth M, et al. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95-and Bax-induced apoptosis. Cell Death Differ 2002; 9: 881-892.
175. Sun M, Meares G, Song L, Jope RS. XIAP associates with GSK3 and inhibits the promotion of intrinsic apoptotic signaling by GSK3. Cell Signal 2009; 21: 1857-65.
176. Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci 2010; 123: 3209-14.
177. Schile AJ, Garcia-Fernandez M, Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev 2008; 22: 2256-66.
178. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its antiapoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98: 8662-7.
179. Seligson DB, Hongo F, Huerta-Yepez S, et al. Expression of Xlinked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007; 13: 6056-6063.
180. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9: 4914-25.
181. Cory S, Adams JM. The Bcl2 family: regulators of the cellular lifeor-death switch. Nat Rev Cancer 2002; 2: 647-56.
182. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
183. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
184. Lin Y, Fukuchi J, Hiipakka RA, et al. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 2007; 17: 531-6.
185. Perlman H, Zhang X, Chen MW, et al. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999; 6: 48-54.
186. Fuzio P, Ditonno P, Lucarelli G, et al. Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. Int J Oncol 2011; 39: 1233-42.
187. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45.
188. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormonereleasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658-62.
189. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324-6.
190. Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988; 2: 1265-75.
191. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 2008; 27: 3986-3998.
192. Lin HK, Hu YC, Yang L, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003; 278: 50902-7.
193. Liu Y, Karaca M, Zhang Z, et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010; 29: 3208-16.
194. Mahajan K, Challa S, Coppola D, et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 2010; 70: 1274-85.
195. Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104: 8438-43.
196. Shu SK, Liu Q, Coppola D, Cheng JQ. Phosphorylation and activation of androgen receptor by Aurora-A. J Biol Chem 2010; 285: 33045-53.
197. Chen S, Xu Y, Yuan X, et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 2006; 103: 15969-74.
198. Gioeli D, Ficarro SB, Kwiek JJ, et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277: 29304-14.
199. Hsu FN, Chen MC, Chiang MC, et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem 2011; 286: 33141-9.
200. Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008; 283: 20989-1001.
201. Gioeli D, Black BE, Gordon V, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006; 20: 503-15.
202. Narayanan R, Yepuru M, Szafran AT, et al. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res 2010; 70: 842-851.
203. Chymkowitch P, Le May N, Charneau P, et al. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J 2011; 30: 468-79.
204. Need EF, Scher HI, Peters AA, et al. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 2009; 150: 2674-82.
205. Zhang L, Altuwaijri S, Deng F, et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175: 489-99.